Figure 4.
Differences in the percentages of CD8 T-cell subpopulations in patients under treatment with omalizumab compared to HD and treated with NID. Percentages of (A) naïve, (B) central memory, (C) effector memory, and (D) effector CD8 T cells in peripheral blood of HD, NID and CSU patients under omalizumab treatment. CSU, chronic spontaneous urticaria; HD, healthy donors (n = 50); NID, non-immunomodulatory drugs (n = 27); OZB, omalizumab (n = 24).
